Amylyx Pharmaceuticals Inc (NAS:AMLX)

Q4 2025 Amylyx Pharmaceuticals Inc Earnings Call Transcript

Mar 3, 2026 / 01:00 PM GMT

Release Date Price: $14.11 (-7.78%)

Transcript 10-K8-K

Key Points

Positve

Amylyx Pharmaceuticals Inc (AMLX) has extended its cash runway into 2028, providing financial stability for future operations.
The company has initiated the pivotal phase 3 Lucidity trial for vexetide, targeting post-bariatric hypoglycemia (PBH), with recruitment now complete.
AMX 114 received fast track designation and demonstrated a favorable safety profile in the phase 1 Lumina trial for ALS, allowing progression to the next cohort.
Amylyx Pharmaceuticals Inc (AMLX) is actively preparing for a potential 2027 commercialization of vexetide, building commercial infrastructure and refining launch strategies.
The company has a strong focus on addressing the unmet medical need in PBH, with an estimated 160,000 people affected in the US, highlighting a significant market opportunity.

Negative

There is uncertainty regarding the placebo response in the phase 3 Lucidity trial, with assumptions of up to a 50% placebo effect despite low placebo response in phase 2.
The company faces challenges in managing PBH due to the lack of approved therapies and the condition's complexity, which requires significant market education and preparation.
Amylyx Pharmaceuticals Inc (AMLX) reported a decrease in cash and marketable securities from $344 million to $317 million between Q3 and Q4 2025.
The company incurred a $4 million milestone payment for AMX 318, which will impact research and development expenses in Q1 2026.
There is a potential risk of non-responders or suboptimal responders to vexetide therapy, as indicated by large standard deviations in phase 2B trial results.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AMLX.OQ - Amylyx Pharmaceuticals Inc
Q4 2025 Amylyx Pharmaceuticals Inc Earnings Call
Mar 03, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning everyone. My name is Jim and I will be your conference operator today. At this time, I would like to welcome everyone to the Amalix Pharmaceuticals 4th quarter and full year 2025 earnings conference call.

All participants will be in a listen-only mode, and after today's presentation, there will be the opportunity to ask questions. To place yourself into a queue, please press star and 1 on your telephone keypad to withdraw your question, you can repeat the steps of and 1.

Please limit yourself to one question with one follow-up today and if you have additional questions, you are invited to rejoin the queue. Please be advised that this call is being recorded at the company's request, and it is

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.